AI-researched · adversarially reviewed · human-checked · corrections public
BEFORE YOU READ — HOW DO YOU RULE?
The Verdict
The annual "full-body checkup" is a product, not a medical recommendation. Randomized trials of general health checks keep finding no reduction in deaths — while the 60-test panels reliably produce false alarms, incidental findings, overdiagnosis, and follow-up cascades that hospitals bill happily. A short list of specific, targeted screenings genuinely saves lives. The executive package is marketing wrapped around that list, with the profitable noise added back in.
A product, not medicine
STRONG EVIDENCE
§ What it actually does
Where the evidence says yes
strongThe targeted core genuinely works: blood pressure checks, cervical screening, colon screening at the right age, HbA1c/glucose in at-risk adults, lipids for risk scoring. These have outcome evidence, individually.
moderateLikely improves detection and management of hypertension and diabetes when part of ongoing primary care (as opposed to a yearly hotel-style event).
weakMay provide reassurance and a doctor relationship some people otherwise never get — worth something, though it is not what the brochure sells.
§ What it doesn't do
Where the marketing outruns the data
contradictedDoes not reduce overall or cardiovascular or cancer mortality — the Cochrane review of randomized trials of general health checks (250,000+ participants) found none, despite marketing built entirely on "early detection saves lives."
contradictedTumor-marker panels (CEA, CA-125, CA 19-9, AFP…) in symptomless people do not work as cancer screening: there is no evidence of benefit and a well-documented harvest of false positives and needless scans.
contradictedWhole-body CT/MRI screening of healthy people is recommended AGAINST by radiology bodies themselves — the incidentaloma yield is enormous and the proven benefit absent.
strongMore tests do not mean more safety: each extra test on a healthy person raises the odds the package finds something meaningless to act on.
§ The Money Map
Who profits, stage by stage
The packagePanels bundle cheap automated tests and price the bundle as premium prevention ("Executive", "Platinum", "Whole Body"). Marginal cost per extra test is trivial; perceived value scales with test count — the incentive is to add noise.
The funnelThe package is often a loss-leader. The margin lives downstream: every borderline result and incidentaloma converts a healthy customer into a patient — scans, biopsies, consultations, sometimes surgery. The cascade is the business model.
The corporate channelEmployer tie-ups and insurance bundles deliver bulk healthy customers annually. In India, hospital chains advertise packages the way airlines advertise seat sales.
The slogan"Early detection saves lives" is true for specific screenings and false as a general principle — the Korea thyroid episode (screening boom → 15× more "cancer" → zero change in deaths) is the definitive receipt.
This pageNo hospital sponsorship, no lab affiliates. See "How we make money."
§ The other side
The strongest case against this verdict
The strongest case against our verdict: the trials behind the Cochrane null are old, mostly European, and predate modern risk scoring and treatments — a well-designed contemporary check focused on blood pressure, lipids, diabetes and risk-appropriate cancer screening might do better than those historical programs. Checks also find genuinely treatable things (severe hypertension, diabetes) in people disconnected from care — for someone who will otherwise see no doctor for a decade, one structured encounter has option value the averages hide. The rational conclusion is "do the targeted list," not "do nothing."
§ Symmetric harms
Harms of using it — and of avoiding it
If you use it
False positives: across a 60-test panel, statistically expect several abnormal results in a perfectly healthy person — each one a doorway to anxiety and follow-up.
Overdiagnosis: real "cancers" that would never have hurt you, treated with real surgery and real complications (Korea, thyroid).
Radiation from CT-containing packages; money — often out of pocket; and false reassurance in the other direction ("all clear" ≠ healthy).
If you avoid it
Skipping the TARGETED list is genuinely dangerous: unmeasured blood pressure, missed cervical/colon screening, undiagnosed diabetes kill quietly. Do not let package-skepticism become screening-nihilism.
People with symptoms: this verdict is about symptomless screening — investigating actual symptoms is not optional.
§ The Minority Report
Who gets hurt when it goes right for everyone else
The hurt group is the healthy: the fitter you are, the worse the package's math treats you.
Healthy young adults buying "peace of mind": near-zero prior probability of disease means most abnormal results are false — they buy anxiety at a premium.
Incidentaloma patients: the thyroidectomies, adrenal workups, and lung biopsies triggered by findings that would never have mattered — with lifelong medication or complications for some.
The scanned-and-irradiated: annual CT-containing packages accumulate radiation exposure with no proven benefit.
The falsely reassured: a "clear" package after which real symptoms get dismissed for months.
How to tell if you might be in this group: Ask of every test in the package: "What guideline recommends this for a symptomless person of my age and risk — and what happens next if it comes back borderline?" A test with no good answer to both is decoration.
§ The alternatives ledger
Everything else, judged by the same standards
strong
Guideline-based targeted screening (age/risk-specific) The evidence-backed core: BP, cervical, colon, lipids, diabetes when at risk, lung CT only for heavy smokers. Cheap, boring, effective.
strong
A home blood-pressure monitor Probably the highest-value 3,000-rupee "checkup" that exists — the killer condition it tracks is common, silent, and treatable.
moderate
Knowing your family history Free, and changes screening recommendations more than most lab panels do.
none
Full-body MRI startups The premium reincarnation of the same product; radiology societies still recommend against screening the symptomless. There is no outcome evidence — only better fonts.
§ Take it to a human
Questions for your doctor
Which items in this package are actually recommended for my age and risk by any guideline?
For each borderline result: what is the follow-up plan, and its cost and risk?
Can I just get the targeted list instead — and what does that cost without the packaging?
Whether a modern, risk-stratified check design could outperform the historical trial programs (research ongoing).
How AI-read imaging will shift the incidentaloma/benefit balance — it could improve it or industrialize the cascade.
§ Corrections
Updates & corrections — public, dated, proud
No corrections yet. Found an error? Challenge it — substantiated challenges are corrected within 48 hours and logged here permanently. Submit a challenge →
§ We dissect ourselves too
How WE make money
This pageNo hospital chains, no diagnostic labs, no imaging startups on this page. Health.AI earns from optional Pro subscriptions. If that changes, this box changes first.
Demand the next dissection
Any disease, drug, supplement, or practice. The queue decides what we dissect next.